
Cigna (CI) Stock Forecast & Price Target
Cigna (CI) Analyst Ratings
Bulls say
Cigna Group is experiencing a positive financial trajectory, highlighted by a 7% year-over-year increase in modified CY25 pre-tax adjusted operating income, reflecting the strength of its core pharmacy benefit management and specialty pharmacy services. Additionally, the company has secured significant client contracts, including a multiyear agreement with Centene and a long-term contract with the Department of Defense, contributing to strong revenue growth. Furthermore, Cigna's Stop-Loss MLR is projected to improve significantly, indicating enhanced profitability and effective pricing strategies aimed at optimizing performance in the competitive health insurance market.
Bears say
Cigna Group's stock outlook is negatively impacted by a significant 4Q24 earnings miss, with adjusted EPS reported at $6.64, which is 15% below consensus estimates and reflects a 2.2% year-over-year decline. The company's total medical enrollment decreased by 3.2% year-over-year, resulting in approximately 633,000 fewer lives covered, further indicating challenges within the Individual and Family Plans segment. Additionally, concerns regarding elevated high-cost claimants in Stop-Loss insurance and declining membership trends raise further doubts about the company's profitability and growth prospects moving forward.
This aggregate rating is based on analysts' research of Cigna and is not a guaranteed prediction by Public.com or investment advice.
Cigna (CI) Analyst Forecast & Price Prediction
Start investing in Cigna (CI)
Order type
Buy in
Order amount
Est. shares
0 shares